Premal H. Patel

Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

David R. Spigel, Thomas J. Ervin, Rodryg Ramlau et al. · Journal of Clinical Oncology · 2013 · 477 citations · Full text

Medicine, Oncology, Pharmacology +17

Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss

Johann S. de Bono, Ugo De Giorgi, Daniel Nava Rodrigues et al. · Clinical Cancer Research · 2018 · 310 citations

Medicine, Oncology, Pharmacology +15

Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC.

David R. Spigel, Thomas J. Ervin, Rodryg Ramlau et al. · Journal of Clinical Oncology · 2011 · 194 citations

Medicine, Oncology, Pharmacology +15

A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors

Cristina Saura, Desamparados Roda, Susana Roselló et al. · Cancer Discovery · 2016 · 171 citations · Full text

Medicine, Oncology, Pharmacology +14

Phase I Study Combining Treatment with Temsirolimus and Sunitinib Malate in Patients with Advanced Renal Cell Carcinoma

Premal H. Patel, P. Senico, Rafael E. Curiel et al. · Clinical Genitourinary Cancer · 2009 · 167 citations

Medicine, Oncology, Pharmacology +11